These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30867499)

  • 1. The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors.
    Coperchini F; Croce L; Denegri M; Awwad O; Ngnitejeu ST; Muzza M; Capelli V; Latrofa F; Persani L; Chiovato L; Rotondi M
    Sci Rep; 2019 Mar; 9(1):4390. PubMed ID: 30867499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The AMPK-activator AICAR in thyroid cancer: effects on CXCL8 secretion and on CXCL8-induced neoplastic cell migration.
    Awwad O; Coperchini F; Pignatti P; Denegri M; Massara S; Croce L; Di Buduo CA; Abbonante V; Balduini A; Chiovato L; Rotondi M
    J Endocrinol Invest; 2018 Nov; 41(11):1275-1282. PubMed ID: 29546654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Interferon-γ on the Basal and the TNFα-Stimulated Secretion of CXCL8 in Thyroid Cancer Cell Lines Bearing Either the RET/PTC Rearrangement Or the BRAF V600e Mutation.
    Rotondi M; Coperchini F; Awwad O; Pignatti P; Di Buduo CA; Abbonante V; Magri F; Balduini A; Chiovato L
    Mediators Inflamm; 2016; 2016():8512417. PubMed ID: 27555670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normal human thyroid cells, BCPAP, and TPC-1 thyroid tumor cell lines display different profile in both basal and TNF-α-induced CXCL8 secretion.
    Coperchini F; Pignatti P; Leporati P; Carbone A; Croce L; Magri F; Chiovato L; Rotondi M
    Endocrine; 2016 Oct; 54(1):123-128. PubMed ID: 26450713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.
    Nucera C; Nehs MA; Nagarkatti SS; Sadow PM; Mekel M; Fischer AH; Lin PS; Bollag GE; Lawler J; Hodin RA; Parangi S
    Oncologist; 2011; 16(3):296-309. PubMed ID: 21355020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin reverts the secretion of CXCL8 induced by TNF-α in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug.
    Rotondi M; Coperchini F; Pignatti P; Magri F; Chiovato L
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E427-32. PubMed ID: 25590211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.
    Salerno P; De Falco V; Tamburrino A; Nappi TC; Vecchio G; Schweppe RE; Bollag G; Santoro M; Salvatore G
    J Clin Endocrinol Metab; 2010 Jan; 95(1):450-5. PubMed ID: 19880792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF-α increases the membrane expression of the chemokine receptor CCR6 in thyroid tumor cells, but not in normal thyrocytes: potential role in the metastatic spread of thyroid cancer.
    Coperchini F; Pignatti P; Carbone A; Bongianino R; Di Buduo CA; Leporati P; Croce L; Magri F; Balduini A; Chiovato L; Rotondi M
    Tumour Biol; 2016 Apr; 37(4):5569-75. PubMed ID: 26577851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB.
    Zhou D; Li Z; Bai X
    Med Sci Monit; 2017 Nov; 23():5321-5329. PubMed ID: 29117154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
    Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
    Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer.
    Gunda V; Cogdill AP; Bernasconi MJ; Wargo JA; Parangi S
    Surgery; 2013 Dec; 154(6):1456-62; discussion 1462. PubMed ID: 24238058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-cancer effects of phenformin in thyroid cancer cell lines and in normal thyrocytes.
    Coperchini F; Croce L; Denegri M; Awwad O; Ngnitejeu ST; Magri F; Chiovato L; Rotondi M
    Oncotarget; 2019 Nov; 10(60):6432-6443. PubMed ID: 31741708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.
    Vanden Borre P; Gunda V; McFadden DG; Sadow PM; Varmeh S; Bernasconi M; Parangi S
    Oncotarget; 2014 Jun; 5(12):3996-4010. PubMed ID: 24994118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective anti-CXCR2 receptor blockade by AZD5069 inhibits CXCL8-mediated pro-tumorigenic activity in human thyroid cancer cells in vitro.
    Coperchini F; Greco A; Petrosino E; Croce L; Teliti M; Marchesi N; Pascale A; Calì B; Pignatti P; Magri F; Uddin M; Rotondi M
    J Endocrinol Invest; 2024 Jun; ():. PubMed ID: 38900374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D Reduces Thyroid Cancer Cells Migration Independently From the Modulation of CCL2 and CXCL8 Chemokines Secretion.
    Coperchini F; Greco A; Croce L; Petrosino E; Grillini B; Magri F; Chiovato L; Rotondi M
    Front Endocrinol (Lausanne); 2022; 13():876397. PubMed ID: 35498406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Combinatorial Strategy for Targeting
    Ghosh C; Kumar S; Kushchayeva Y; Gaskins K; Boufraqech M; Wei D; Gara SK; Zhang L; Zhang YQ; Shen M; Mukherjee S; Kebebew E
    Clin Cancer Res; 2020 Apr; 26(8):2022-2036. PubMed ID: 31937621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines.
    Varmeh S; Vanden Borre P; Gunda V; Brauner E; Holm T; Wang Y; Sadreyev RI; Parangi S
    Surgery; 2016 Jan; 159(1):152-62. PubMed ID: 26456124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin reduces thyroid cancer cells migration in vitro by inhibiting CXCL8 and CCL2: An additional anti-tumor effect of the drug.
    Coperchini F; Greco A; Croce L; Pignatti P; Muzza M; Petrosino E; Teliti M; Magri F; Rotondi M
    Biomed Pharmacother; 2024 Jan; 170():115974. PubMed ID: 38056240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.
    Hanly EK; Bednarczyk RB; Tuli NY; Moscatello AL; Halicka HD; Li J; Geliebter J; Darzynkiewicz Z; Tiwari RK
    Oncotarget; 2015 Nov; 6(37):39702-13. PubMed ID: 26284586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance.
    Oikonomou E; Koc M; Sourkova V; Andera L; Pintzas A
    PLoS One; 2011; 6(6):e21632. PubMed ID: 21738740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.